In this multicentre study a controlledrelease formulation of levodopa and the decarboxylase inhibitor benserazide (Madopar CR) was evaluated in patients with Parkinson's disease exhibiting doserelated fluctuations in motor performance in response to conventional levodopa preparations. The effect of Madopar CR, with or without conventional levodopa/benserazide, on the proportion of time spent "on", "off" or "intermediate" was compared with that ofprevious conventional levodopa/decarboxylase inhibitor therapy. Evaluation of the two periods of optimum therapy was based on both patient diary data and investigator opinion. Forty seven patients completed the study but full patient diaries were available for only 37. The mean optimum total daily dosage of conventional Madopar was 820 mg taken in a mean of 6-4 doses, compared with a mean optimum daily dosage of combined Madopar CR and conventional Madopar of 1088 mg, taken in a mean of 5 2 doses. Conventional Madopar was taken in addition to Madopar CR in all but eight patients. Madopar CR was felt to be advantageous in 83% and disadvantageous in 11% of patients completing the study. Considering the 37 patients for whom diary data were available, Madopar CR therapy resulted in an increase in the mean time spent "on" (p = 0-016) and a decrease in the mean time spent "off" (p = 0-029) compared with conventional Madopar alone. Individually 25 out of 37 had an increase in "on" time and 19 out of 37 experienced a decrease in "off" time. Thus Madopar CR was found to be beneficial in a significant proportion of patients experiencing fluctuations in response to conventional levodopa.
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Levodopa plus a decarboxylase inhibitor remains the most effective treatment for Parkinson's disease. However, during the course of sustained therapy with levodopa, disabling fluctuations in motor control emerge so that after five years at least 50%/, of patients experience fluctuations in mobility throughout the day.'`Although the mechanisms underlying these changes are poorly understood the maintenance of stable plasma levodopa concentrations by means of intravenous infusions of levodopa has been shown to reduce swings in motor performance dramatically.' This recognition of the importance of steady state plasma and brain concentrations of levodopa has renewed interest in oral controlled-release preparations, which offer the possibility of a more practical means of achieving relatively stable plasma levodopa concentrations.
In comparison to the conventional levodopa/ benserazide preparation, Madopar CR* has been shown to exhibit sustained-release characteristics, that is, it gives rise to sustained plasma levodopa concentrations.7" However the bioavailability of the CR form is reduced, being on average 600/ that of standard Madopar so that higher doses are usually required and there is a lower, delayed peak plasma concentration of levodopa.7" Clinical experience so far indicates that overall "on" time is generally increased by Madopar CR but for a number of patients there is an unacceptable delay in turning "on" when Madopar CR 
Discussion
In this open, multicentre study we found that Madopar CR increased the amount of waking time spent "on" and decreased time "spent off' in a substantial proportion of patients who completed the study. Fluctuations in response were not eradicated and in this study oral controlled-release therapy was not as effective as intravenous levodopa therapy has been shown to be.8 Nevertheless, Madopar CR was of significant clinical advantage in three quarters of those who completed the trial.
There were a large number of patient withdrawals. Halfof these patients withdrew before
receiving Madopar CR and this illustrates the difficulty in maintaining adequate numbers of patients in a trial of this type. However, lack of efficacy of the controlled-release formulation was the reason given for 10 of the 14 patients who withdrew during Madopar CR therapy. Four methods of dose titration were used in this study and it is likely that with more experience in titrating the optimum dose of Madopar CR some of these patients would have remained in the trial. Some patients experience a delay in onset of effect with Madopar CR.>" Because of the importance attached by patients to predictability of response,"2 it is not surprising that the optimum therapeutic regime for most patients included at least one dose of conventional Madopar, usually taken together with the first morning dose of Madopar CR.
In common with the majority of previous studies, overall dosage in the Madopar CR phase of the study was considerably higher than during the optimum therapy with standard Madopar. However, it is unlikely that improvements in condition were due simply to an increase in dosage. This would normally be accompanied by an escalation in adverse effects, which was not observed here. Furthermore this possible explanation does not take into account the reduced bioavailablity of the controlled-release form, which is on average only 60% that of standard Madopar.8 There was a slight reduction in the number of doses taken per day when therapy was changed to Madopar CR. A significant reduction in dose frequency might have been anticipated with a controlled-release formulation, however, improved clinical response via the maintenance of stable plasma concentrations was the primary objective rather than dose reduction.
Despite the higher overall dosage the Madopar CR phase of the study was not associated with a significantly greater incidence of adverse events. In view of the lack of quantitative data it is possible that the increase in time "on" brought about by Madopar CR was accompanied by an increased incidence of dyskinesia. Although this cannot be ruled out, the absence in reporting of dyskinesia as an adverse event during Madopar CR therapy, coupled with the generally positive views of the investigators, make this unlikely.
In some studies nocturnal akinesia and overall sleep quality have been reported to be improved by Madopar CR8 1114 and the results of a study in which Madopar CR was taken at bedtime specifically to combat nocturnal Parkinsonian problems are encouraging. '3 In our study mean measures of sleep quality and quantity did not differ to any great extent when standard Madopar was compared with Madopar CR. However, patients are notoriously inaccurate at assessing sleep duration and it would be unwise to assume that there were no differences between the two treatments in this respect. Another possibility is that sleep problems were not a prominent feature of this group of patients, as the relatively low scores for sleep quality (corresponding to good sleep) throughout the trial would indicate.
For a substantial number of Parkinsonian patients with dose-related fluctuations in motor performance significant clinical advantage was derived from a combination of Madopar CR and standard Madopar. The proportion of time spent "on" was increased and time "off' decreased. The main disadvantages of this therapy were that dose titration was difficult without previous experience of Madopar CR and it was not possible to predict which patients were likely to benefit.
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*Madopar is a trade mark. Madopar CR was previously called Madopar HBS and is referred to by this name in some publications.
